Q3 2026 Marksans Pharma Ltd Earnings Call Transcript
Key Points
- Marksans Pharma Ltd (BOM:524404) reported a 10.6% year-on-year increase in operating revenue for Q3 FY26, reaching an all-time high of INR754 crores.
- The US and North American markets showed strong performance with a 16.9% year-on-year revenue increase, driven by volume growth and seasonal demand.
- The company achieved a gross margin expansion to 58.1%, attributed to softening raw material prices and a favorable product mix.
- EBITDA for Q3 FY26 increased by 23.2% year-on-year, with an EBITDA margin expansion to 21.3%, driven by operating leverage and improved cost efficiencies.
- Marksans Pharma Ltd (BOM:524404) remains debt-free with a cash balance of INR824.2 crores as of December 31, 2025, providing a strong financial position for future growth.
- The UK and EU markets experienced flat revenue growth due to ongoing pricing pressures, impacting overall performance in these regions.
- Employee costs have increased, partly due to new labor code accounting and wage changes, affecting overall profitability.
- The company's RX product segments in the UK faced high single-digit price erosion, impacting revenue and margins.
- Despite strong performance in the US, geopolitical uncertainties and tariff issues have posed challenges, affecting growth momentum.
- The company's expansion into new markets like Europe and Canada is still in early stages, with significant time required before meaningful revenue contributions are realized.
Ladies and gentlemen, good day and welcome to the Marksans Pharma Q3 FY26 earnings conference call. (Operator Instructions). Please note that this conference is being recorded. I now hand the conference over to Mr. Nitin Agarwal from Dam Capital Advisors. Thank you and over to you, sir.
Hi, thank you. Good afternoon, everyone, and a very warm welcome to Marksans Pharma Q3 FY26 earnings conference call hosted by Dam Capital Advisors Limited. On the call today, we have, representing Marksans Pharma Management, Mr. Mark Saldanha, founder, Chairman and managing director, and Mr. Jitendra Sharma, Chief Financial Officer.
I will hand over the call to the management team to make the opening comments, and then we'll open the floor for questions. Please go ahead, sir.
Thank you, Nitin. Welcome everyone and thank you for joining us for our Q3, and 9 months at FY26 earning
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
